Company Filing History:
Years Active: 2004
Title: Jurgen Corthals: Innovator in Cancer Research
Introduction
Jurgen Corthals is a notable inventor based in Brussels, Belgium. He has made significant contributions to the field of cancer research, particularly through his work on tumor-associated genes. His innovative approach has led to advancements in the diagnosis and treatment of cancer.
Latest Patents
Corthals holds a patent for "Mage-A3 peptides presented by HLA class molecules." This invention describes HLA class II binding peptides encoded by the MAGE-A3 tumor-associated gene. The patent also includes nucleic acids encoding such peptides and antibodies related to them. These peptides are designed to stimulate the activity and proliferation of CD4 T lymphocytes. Additionally, the patent provides methods and products for diagnosing and treating conditions characterized by the expression of the MAGE-A3 gene. He has 1 patent to his name.
Career Highlights
Jurgen Corthals is affiliated with the Ludwig Institute for Cancer Research Limited, where he continues to push the boundaries of cancer research. His work has been instrumental in developing new therapeutic strategies aimed at improving patient outcomes.
Collaborations
Corthals has collaborated with esteemed colleagues such as Erwin Schultz and Pascal Chaux. These partnerships have fostered a collaborative environment that enhances the research and development of innovative cancer treatments.
Conclusion
Jurgen Corthals is a prominent figure in cancer research, with a focus on innovative solutions for diagnosing and treating cancer. His contributions through patents and collaborations highlight his commitment to advancing medical science.